A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This single-center study will be a single-dose, randomized, double-blind, placebo- and
active-controlled crossover study with a single inpatient treatment visit. The abuse
potential of single oral doses of EB-1020 IR (400 mg, 800 mg) will be compared with that of
placebo and d-amphetamine (20 mg, 40 mg; active control) in healthy recreational stimulant
users. Subjects will participate in a medical Screening visit (Visit 1), one 4-day inpatient
Qualification Phase (Visit 2), one 11-day inpatient Treatment Phase (Visit 3), and a safety
Follow-up visit (Visit 4).